Comparative Pharmacology
Head-to-head clinical analysis: BETOPTIC versus METOPROLOL TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETOPTIC versus METOPROLOL TARTRATE.
BETOPTIC vs METOPROLOL TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Competitive beta-1 adrenergic receptor antagonist with weak beta-2 blocking activity; reduces heart rate, contractility, and AV conduction.
Instill 1 drop of 0.5% solution in the affected eye(s) twice daily.
Initial dose 100 mg daily in divided doses (e.g., 50 mg twice daily) orally; may increase weekly up to 200-450 mg daily in 2-3 divided doses.
None Documented
None Documented
Terminal elimination half-life: 4–5 hours. With topical ophthalmic administration, systemic absorption is minimal, so half-life refers to IV data.
3–4 hours (terminal) in healthy adults; prolonged to 7–8 hours in severe hepatic impairment; no change in renal impairment.
Renal (fecal <5%). 60% as unchanged drug, 40% as inactive metabolites.
Renal: 95% as metabolites, <5% unchanged. Fecal: negligible.
Category C
Category C
Beta-Blocker
Beta-Blocker